ASCO/EHA 2025: Novartis highlights new data on Kisqali, Pluvicto, Scemblix, and Fabhalta
Novartis will present data from 60 company or investigator sponsored abstracts that have the potential to change clinical practice, at the 2025 American Society of Clinical Oncology (ASCO)… read more.